Patient Top Concerns At and Since Diagnosis | Nathan Sweeney, PhD | ASH 2022

Patient Top Concerns At and Since Diagnosis | Nathan Sweeney, PhD | ASH 2022
Revlimid Refractory Patients in Daratumumab Clinical Trials | Binod Dhakal, MD | ASH 2022
iStopMM Trial - Covid Vaccine and Impact on Myeloma | Malin Hultcrantz, MD, PhD | ASH 2022
Updates on Teclistamab, Talquetamab, and CARVYKTI | Mark Wildgust, PhD | ASH 2022
Treatment vs Quality of Life in Older Patients | Sara Tinsley Vance, PhD, APRN | ASH 2022
Prospective Evaluation of the Biology of Aggressive Myeloma Lesions After Induction | ASH 2022
Detecting Myeloma with Single Cell Sequencing | Scott Goldsmith, MD | ASH 2022
What to Look Forward to at ASH | Ola Landgren, MD, PhD | ASH 2022
BETA - Are hypomethylating agents used alone or in combination?
BETA - Who are the most appropriate patients to use hypomethylating agents?
BETA - What is the definition of relapsed AML?
BETA - What is the difference between relapsed and refractory AML?
(Guest Lecture): Relapsed Refractory Multiple Myeloma - Krina Patel, MD, MSc | RT Irvine, CA Nov 5, 2022
(Guest Lecture) November 2022 - Integrative Medicine: Ideas for Myeloma Treatment
(Guest Lecture): November 2022 - How Myeloma Frontline Therapy is Changing - Ajai Chari, MD